# ZYNRELEF® (bupivacaine-meloxicam) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bupivacaine-meloxicam

> The FDA approved ZYNRELEF® (bupivacaine-meloxicam), sponsored by HERON THERAPEUTICS, INC. /DE/ (HRTX), on Sep 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ZYNRELEF® (bupivacaine-meloxicam) |
| Codes |  |
| Sponsor | HERON THERAPEUTICS, INC. /DE/ (HRTX) https://sec-api.dev/companies/hrtx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 30, 2019: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22211988_2022_Orig1s000OtherActionLtrs.pdf%22

### June 26, 2020: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22211988_2022_Orig1s000OtherActionLtrs.pdf%22

### Dec 2021: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124626): "In December 2021, the FDA approved an expansion of ZYNRELEF's indication to include foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures." https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/hrtx-ex99_1.htm

### January 23, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124626): "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-452721): "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." https://www.sec.gov/Archives/edgar/data/818033/000119312526452721/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341300): "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." https://www.sec.gov/Archives/edgar/data/818033/000119312526341300/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-215752): "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073502): "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-008631): "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." https://www.sec.gov/Archives/edgar/data/818033/000119312526008631/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-263617): "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-105474): "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." https://www.sec.gov/Archives/edgar/data/818033/000095017025105474/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063973): "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." https://www.sec.gov/Archives/edgar/data/818033/000095017025063973/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-028372): "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." https://www.sec.gov/Archives/edgar/data/818033/000095017025028372/hrtx-ex99_1.htm

### Sep 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-27, last confirmed 2025-02-27.
- SEC Form 10-K (accession 0000950170-25-028374): "In September 2024, the FDA approved our Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ("VAN"), which will replace the current vented vial spike." https://www.sec.gov/Archives/edgar/data/818033/000095017025028374/hrtx-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bupivacaine-meloxicam.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ZYNRELEF® (bupivacaine-meloxicam) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bupivacaine-meloxicam

```bibtex
@misc{secapidev_pdufa_bupivacaine_meloxicam_20261116,
  title        = {ZYNRELEF® (bupivacaine-meloxicam) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bupivacaine-meloxicam}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bupivacaine_meloxicam_20261116","title":"ZYNRELEF® (bupivacaine-meloxicam) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bupivacaine-meloxicam","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
